EGFR and neoplasm: NGS: 23.7% detection rate in cfDNA, 61.5% detection rate in tumor tissue; 56.9% false negative rate for cfDNAProgression Free Survival (PFS): For patients positive for EGFR mutations, those who received gefitinib had longer PFS than those who received carboplatin-paclitaxel.